Search clinical trials for: Capecitabine, Nab-Paclitaxel

Total 7853 results

Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Abramson Cancer Center of the University of Pennsylvania

Completed

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Pancreatic Cancer

United States
Asan Medical Center
Ulsan University Hospital; Bundang CHA Hospital

Completed

Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

Korea, Republic of
Xian-Jun Yu

Completed

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
Seoul National University Hospital

Unknown

The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Chemotherapy Effect

Korea, Republic of
Western Regional Medical Center

Terminated

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer | Pancreatic Carcinoma Non-resectable

United States
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal
Sun Yat-sen University

Completed

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

HER2 Positive Breast Cancer

China
Universidad de Granada

Completed

Beer or Ethanol Effects on the Response to High Intensity Interval Training: A Controlled Study in Healthy Individuals (BEER-HIIT)

Exercise | Drinking, Alcohol

Spain
Fudan University

Not yet recruiting

Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer (BETTER)

Non-small Cell Lung Cancer Metastatic
Scandion Oncology A/S
Alcedis GmbH

Recruiting

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. (PANTAX-Ib)

Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic Adenocarcinoma

Denmark, Germany
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer

Breast Cancer,Her2 Positive

China
Sun Yat-sen University

Recruiting

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

PDAC - Pancreatic Ductal Adenocarcinoma

China
Lund University

Recruiting

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)

Pancreatic Cancer | Periampullary Cancer | Periampullary Adenocarcinoma

Sweden
HonorHealth Research Institute
Celgene

Active, not recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Hacettepe University
Celgene

Completed

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

Pancreatic Neoplasm
Threshold Pharmaceuticals

Terminated

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Pancreatic Cancer

United States
Hoffmann-La Roche

Terminated

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Cancer

France, Canada, Denmark, United States
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Zhejiang Cancer Hospital

Recruiting

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Gastric Cancer | Peritoneal Metastases | Ascites, Malignant

China
RenovoRx

Recruiting

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (TIGeR-PaC)

Locally Advanced Pancreatic Cancer

United States, Belgium
Dana-Farber Cancer Institute
AVEO Pharmaceuticals, Inc.

Completed

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Pharmacyclics LLC.

Completed

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Metastatic Pancreatic Adenocarcinoma

Spain, Italy, Korea, Republic of, United States, Belgium, United Kingdom, Germany, France
Celgene

Terminated

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Pancreatic Neoplasms | Cholestasis

United States, Germany
Incyte Corporation

Terminated

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Hodgkin's Lymphoma | Solid Tumor | Metastatic Cancer | Advanced Cancer | NHL (Non-Hodgkin Lymphoma) | UC (Ureter and Urethera)

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)

Advanced or Metastatic Solid Tumors

Chile, Hungary, Korea, Republic of, South Africa, Spain, Japan
Celgene

Terminated

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Stage IV (Metastatic) Breast Cancer

United States
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
Borstkanker Onderzoek Groep
Roche Pharma AG; Teva Pharma

Completed

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (Stop&Go)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Netherlands
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Breast Neoplasms

China
Hoffmann-La Roche

Completed

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Breast Cancer, Colorectal Cancer

New Zealand, Australia, United Kingdom
Osijek University Hospital

Completed

The Influence of Postoperative Analgesia on Systemic Inflammatory Response and POCD After Femoral Fractures Surgery

Postoperative Cognitive Dysfunction

Croatia
EQRx International, Inc.

Terminated

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NSCLC

United States
University of Washington
AstraZeneca

Terminated

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

HIV Infections

United States, Puerto Rico, Zimbabwe, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Non-Small Cell Lung Cancer

Poland, United States, Brazil, France, Guatemala, Hungary, Japan, Korea, Republic of, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306)

Non-small Cell Lung Cancer (NSCLC)
Nektar Therapeutics

Completed

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)

Breast Cancer | Metastasis

United States, Australia, Belgium, Canada, France, Israel, Italy, Portugal, Spain, United Kingdom
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer (STELA)

Metastatic Breast Cancer

United States
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Fudan University

Not yet recruiting

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Pancreatic Cancer
Bruno Bockorny
Dana-Farber Cancer Institute; Agenus Inc.

Not yet recruiting

AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma

United States
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (APA)

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and Neck

United States

Search clinical trials for: Capecitabine, Nab-Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations